Merus N.V. (MRUS)
Company Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands.
Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145.
The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
| Country | Netherlands |
| Founded | 2003 |
| IPO Date | May 19, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 164 |
| CEO | Dr. Sven Ante Lundberg M.D. |
Contact Details
Address:
Yalelaan 62 3584 Cm Utrecht, P7 3584 CM Netherlands | |
| Phone | 31 030 253 8800 |
| Website | merus.nl |
Stock Details
| Ticker Symbol | MRUS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651311 |
| CUSIP Number | N5749R100 |
| ISIN Number | NL0011606264 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sven Ante Lundberg M.D. | Chief Executive Officer, President, Principal Financial Officer and Executive Director |
| Peter B. Silverman J.D. | Executive Vice President, General Counsel, Chief Intellectual Property Officer and Head of Utrecht and US Legal |
| Hui Liu Ph.D. | Chief Business Officer, Executive Vice President and Head of Merus U.S. |
| Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor |
| Harry Shuman | Chief Accounting Officer |
| Cornelis Adriaan de Kruif Ph.D. | Chief Technology Officer and Executive Vice President |
| Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer and Senior Vice President |
| Jillian Connell | Vice President of Investor Relations and Corporate Communications |
| Alexander Berthold Hendrik Bakker Ph.D. | Chief Development Officer and Executive Vice President |
| Dr. Andrew Joe M.D. | Chief Medical Officer and Senior Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 1, 2023 | 144 | Filing |
| May 30, 2023 | 8-K | Current Report |
| May 23, 2023 | 8-K | Current Report |
| May 4, 2023 | 10-Q | Quarterly Report |
| Apr 28, 2023 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2023 | PRE 14A | Other preliminary proxy statements |
| Apr 17, 2023 | 8-K | Current Report |
| Mar 10, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 28, 2023 | RW | Filing |
| Feb 28, 2023 | 10-K | Annual Report |